Dorzagliatin was included in China's National Reimbursement Drug List (NRDL) at the end of 2023. The time reported in the article is 2022, which is incorrect.
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
沪公网安备 31011502013809号 Privacy Statement Terms of Use
